Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

Stock Information for Atai Beckley N.V

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Atai Beckley N.V

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics Adds to Management Team to Support Expansion and Growth
Vivos Therapeutics Receives Medicare Approval for VidaSleep(TM) Oral Appliance
New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.